StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3038% below fair value
$0.53−0.01 (-2.41%)

Close on Nov 13, 2026Market cap $81.19MP/E –Yield –

Coherus Oncology gross margin

Gross margin is gross profit as a percentage of revenue.

Coherus Oncology's gross margin for the twelve months ending Sep 30, 2026 was 69.8%. For fiscal 2025 it was 67.2%, against 66.9% the year before. The highest annual figure on record is 95.2% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202567.2%+0.3
FY2024Dec 31, 202466.9%+28.7
FY2023Dec 31, 202338.2%−28.6
FY2022Dec 31, 202266.8%−15.6
FY2021Dec 31, 202182.4%−9.7
FY2020Dec 31, 202092.1%−3.1
FY2019Dec 31, 201995.2%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202671.3%+3.5
Q2 FY2026Jun 30, 202670.4%+3.5
Q1 FY2026Mar 31, 202669.0%+3.9
Q4 FY2025Dec 31, 202568.3%+3.8
Q3 FY2025Sep 30, 202567.8%+12.9
Q2 FY2025Jun 30, 202566.9%−15.5
Q1 FY2025Mar 31, 202565.1%+27.4
Q4 FY2024Dec 31, 202464.4%+56.8
Q3 FY2024Sep 30, 202454.9%−1.2
Q2 FY2024Jun 30, 202482.4%+24.7
Q1 FY2024Mar 31, 202437.7%−10.3
Q4 FY2023Dec 31, 20237.6%−61.1
Q3 FY2023Sep 30, 202356.1%+33.7
Q2 FY2023Jun 30, 202357.7%−23.6
Q1 FY2023Mar 31, 202348.0%−36.4
Q4 FY2022Dec 31, 202268.7%−14.8
Q3 FY2022Sep 30, 202222.4%−51.8
Q2 FY2022Jun 30, 202281.3%+0.3
Q1 FY2022Mar 31, 202284.4%−6.5
Q4 FY2021Dec 31, 202183.5%−5.9
Q3 FY2021Sep 30, 202174.2%−17.9
Q2 FY2021Jun 30, 202180.9%−11.6
Q1 FY2021Mar 31, 202191.0%−3.1
Q4 FY2020Dec 31, 202089.4%−4.3
Q3 FY2020Sep 30, 202092.1%−2.2
Q2 FY2020Jun 30, 202092.5%−6.8
Q1 FY2020Mar 31, 202094.1%+0.1
Q4 FY2019Dec 31, 201993.7%–
Q3 FY2019Sep 30, 201994.2%–
Q2 FY2019Jun 30, 201999.3%–
Q1 FY2019Mar 31, 201994.0%–

More Coherus Oncology figures

See a number that looks wrong?